| Literature DB >> 18725320 |
John A Robinson1, Steve Demarco, Frank Gombert, Kerstin Moehle, Daniel Obrecht.
Abstract
Using a biologically relevant peptide or protein structure as a starting point for lead identification represents one of the most powerful approaches in modern drug discovery. Here, we focus on the protein epitope mimetic (PEM) approach, where folded 3D structures of peptides and proteins are taken as starting points for the design of synthetic molecules that mimic key epitopes involved in protein-protein and protein-nucleic acid interactions. By transferring the epitope from a recombinant to a synthetic scaffold that can be produced by parallel combinatorial methods, it is possible to optimize target affinity and specificity as well as other drug-like ADMET properties. The PEM technology is a powerful tool for target validation, and for the development of novel PEM-based drugs.Mesh:
Substances:
Year: 2008 PMID: 18725320 DOI: 10.1016/j.drudis.2008.07.008
Source DB: PubMed Journal: Drug Discov Today ISSN: 1359-6446 Impact factor: 7.851